Week 1: Pharmacogenomics Discussion Post (Original Post due Wednesday, Peer Response
due Sunday)
In your initial post, respond to the following scenario (Hint: use the pharmgkb website to guide
your responses):
1. Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient
the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that
the patient carries the HLA-B*5701 allele.
Describe what these results mean.
Should the nurse practitioner prescribe abacavir in this case? If not, state why.
2. A patient is prescribed antiplatelet therapy (clopidogrel) following an acute myocardial
infarction (MI). Six months later, the patient suffers another acute MI. The patient has
been adherent to therapy and the nurse practitioner suspects that clopidrogel may have
been ineffective. How might genetic testing have been beneficial in this case?
3. Identify 2 limitations of pharmacogenomics testing. Explain.
4. Identify 2 ethical concerns of using pharmacogenomics testing. Explain.
due Sunday)
In your initial post, respond to the following scenario (Hint: use the pharmgkb website to guide
your responses):
1. Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient
the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that
the patient carries the HLA-B*5701 allele.
Describe what these results mean.
Should the nurse practitioner prescribe abacavir in this case? If not, state why.
2. A patient is prescribed antiplatelet therapy (clopidogrel) following an acute myocardial
infarction (MI). Six months later, the patient suffers another acute MI. The patient has
been adherent to therapy and the nurse practitioner suspects that clopidrogel may have
been ineffective. How might genetic testing have been beneficial in this case?
3. Identify 2 limitations of pharmacogenomics testing. Explain.
4. Identify 2 ethical concerns of using pharmacogenomics testing. Explain.
